<p>Immunotherapy has been a pillar of the renal cell carcinoma (RCC) treatment landscape for over three decades. Some of the earliest cancer immunotherapies available, such as interleukin 2 and interferon-alpha, have resulted in complete responses, but only in a small number of patients. Immune checkpoint inhibitors (ICIs), however, have demonstrated improved response rates and prolonged survival for a greater number…
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0
Journal for ImmunoTherapy of Cancer | | McKay, R. R., Ajmera, A., Atkins, M. B., Barata, P. C., Bergerot, C., Bukavina, L., Choueiri, T. K., Desai, A., Hakimi, A. A., Poteat, S., Powles, T., Rini, B. I., Shuch, B., Signoretti, S., Siva, S., Xu, W., Yip, W., Zhang, T., Pal, S. K.
Topics: blood-cancer, kidney-cancer, cervical-cancer, immunotherapy, clinical-trials
Read the full article at Journal for ImmunoTherapy of Cancer